Evaluation of Quality Improvement for People with Type 2 Diabetes

An evaluation of two large-scale quality improvement interventions embedded with a national clinical audit to improve the care for young adults with type 2 diabetes (EQUIPD2)

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN52205353

Enrollment

1263

Registered

2025-03-12

Start date

2025-03-17

Completion date

Unknown

Last updated

2026-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes Nutritional, Metabolic, Endocrine

Interventions

We will undertake a three-arm cluster randomized controlled trial to evaluate the effectiveness of NDA feedback with low- or medium intensity facilitation compared to NDA feedback alone in reducing th

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Primary care networks in England

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
HbA1c level at 18 months post-randomisation in young adults (18-39 years) with type 2 diabetes and baseline HbA1c =58 mmol/mol measured using measured using National Diabetes Audit data	—

Secondary

Measure	Time frame
Measured in young adults (18-39 years) with type 2 diabetes and baseline HbA1c =58 mmol/mol: 1. HbA1c measured using data routinely collected as part of the National Diabetes Audit over the 18-month follow-up period 2. Prescription of both metformin and SGLT2 inhibitor measured using data routinely collected as part of the National Diabetes Audit over the 18-month follow-up period 3. Statin prescription measured using data routinely collected as part of the National Diabetes Audit over the 18-month follow-up period 4. Proportion receiving NICE-recommended care processes in the preceding 12 months: blood pressure check; serum creatinine testing; urinary albumin: creatinine ratio testing; foot examination and risk classification; smoking status; retinal screening; body mass index; and referral to a structured education programme measured using data routinely collected as part of the National Diabetes Audit over the 18-month follow-up period	—

Measure

Time frame

Measured in young adults (18-39 years) with type 2 diabetes and baseline HbA1c =58 mmol/mol: 1. HbA1c measured using data routinely collected as part of the National Diabetes Audit over the 18-month follow-up period 2. Prescription of both metformin and SGLT2 inhibitor measured using data routinely collected as part of the National Diabetes Audit over the 18-month follow-up period 3. Statin prescription measured using data routinely collected as part of the National Diabetes Audit over the 18-month follow-up period 4. Proportion receiving NICE-recommended care processes in the preceding 12 months: blood pressure check; serum creatinine testing; urinary albumin: creatinine ratio testing; foot examination and risk classification; smoking status; retinal screening; body mass index; and referral to a structured education programme measured using data routinely collected as part of the National Diabetes Audit over the 18-month follow-up period

—

Countries

United Kingdom

Contacts

Public ContactMichael Sykes

michael.sykes@northumbria.ac.uk+44 (0)191 232 6002

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026